NASDAQ:AXSM Axsome Therapeutics (AXSM) Stock Price, News & Analysis $119.18 +6.97 (+6.21%) As of 02:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Axsome Therapeutics Stock (NASDAQ:AXSM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Axsome Therapeutics alerts:Sign Up Key Stats Today's Range$113.61▼$120.0050-Day Range$95.65▼$129.1752-Week Range$64.11▼$139.13Volume539,894 shsAverage Volume684,874 shsMarket Capitalization$5.87 billionP/E RatioN/ADividend YieldN/APrice Target$169.87Consensus RatingBuy Company OverviewAxsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Read More… Axsome Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks97th Percentile Overall ScoreAXSM MarketRank™: Axsome Therapeutics scored higher than 97% of companies evaluated by MarketBeat, and ranked 82nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingAxsome Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 16 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAxsome Therapeutics has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Axsome Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Axsome Therapeutics are expected to grow in the coming year, from ($2.79) to $2.82 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Axsome Therapeutics is -19.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Axsome Therapeutics is -19.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxsome Therapeutics has a P/B Ratio of 101.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Axsome Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted11.68% of the float of Axsome Therapeutics has been sold short.Short Interest Ratio / Days to CoverAxsome Therapeutics has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Axsome Therapeutics has recently decreased by 14.17%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAxsome Therapeutics does not currently pay a dividend.Dividend GrowthAxsome Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.5 / 5Environmental Score-1.03 Percentage of Shares Shorted11.68% of the float of Axsome Therapeutics has been sold short.Short Interest Ratio / Days to CoverAxsome Therapeutics has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Axsome Therapeutics has recently decreased by 14.17%, indicating that investor sentiment is improving significantly. News and Social Media3.4 / 5News Sentiment1.16 News SentimentAxsome Therapeutics has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 22 news articles for Axsome Therapeutics this week, compared to 10 articles on an average week.Search InterestOnly 10 people have searched for AXSM on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.MarketBeat Follows10 people have added Axsome Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Axsome Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $393,210.00 in company stock.Percentage Held by Insiders22.40% of the stock of Axsome Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions81.49% of the stock of Axsome Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Axsome Therapeutics' insider trading history. Receive AXSM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AXSM Stock News HeadlinesAxsome Therapeutics, Inc. (AXSM) Q1 2025 Earnings Call TranscriptMay 5 at 12:04 PM | seekingalpha.comAxsome Therapeutics beats Q1 expectations, shares riseMay 5 at 7:55 AM | investing.comTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.May 5, 2025 | Porter & Company (Ad)Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 5 at 7:00 AM | globenewswire.comCantor Fitzgerald Issues Positive Estimate for AXSM EarningsMay 5 at 2:53 AM | americanbankingnews.comAxsome Therapeutics (AXSM) Expected to Announce Quarterly Earnings on MondayMay 4 at 2:09 AM | americanbankingnews.comAxsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health MonthMay 1, 2025 | financialpost.comAxsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health MonthMay 1, 2025 | globenewswire.comSee More Headlines AXSM Stock Analysis - Frequently Asked Questions How have AXSM shares performed this year? Axsome Therapeutics' stock was trading at $84.61 at the beginning of 2025. Since then, AXSM shares have increased by 40.9% and is now trading at $119.1750. View the best growth stocks for 2025 here. How were Axsome Therapeutics' earnings last quarter? Axsome Therapeutics, Inc. (NASDAQ:AXSM) released its quarterly earnings results on Monday, May, 5th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.23) by $0.43. Axsome Therapeutics had a negative trailing twelve-month return on equity of 223.51% and a negative net margin of 74.47%. Read the conference call transcript. When did Axsome Therapeutics IPO? Axsome Therapeutics (AXSM) raised $52 million in an IPO on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. acted as the underwriters for the IPO and Brean Capital was co-manager. Who are Axsome Therapeutics' major shareholders? Axsome Therapeutics' top institutional shareholders include Assenagon Asset Management S.A. (1.29%), Principal Financial Group Inc. (0.61%), Bank of New York Mellon Corp (0.27%) and Iridian Asset Management LLC CT (0.22%). Insiders that own company stock include Roger Jeffs, Nick Pizzie, Mark Coleman, Mark E Saad and Mark L Jacobson. View institutional ownership trends. How do I buy shares of Axsome Therapeutics? Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Axsome Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Axsome Therapeutics investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and Marinus Pharmaceuticals (MRNS). Company Calendar Last Earnings2/18/2025Today5/05/2025Next Earnings (Estimated)5/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AXSM CIK1579428 Webaxsome.com Phone(212) 332-3241Fax212-320-0245Employees380Year FoundedN/APrice Target and Rating Average Stock Price Target$169.87 High Stock Price Target$216.00 Low Stock Price Target$105.00 Potential Upside/Downside+51.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($5.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-287,220,000.00 Net Margins-74.47% Pretax Margin-74.44% Return on Equity-223.51% Return on Assets-39.88% Debt Debt-to-Equity Ratio3.22 Current Ratio2.11 Quick Ratio2.04 Sales & Book Value Annual Sales$385.69 million Price / Sales14.32 Cash FlowN/A Price / Cash FlowN/A Book Value$1.18 per share Price / Book95.09Miscellaneous Outstanding Shares49,219,000Free Float37,842,000Market Cap$5.52 billion OptionableOptionable Beta0.46 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:AXSM) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Axsome Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.